Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score

Mayo Clinic Proceedings

Volumn 86, Issue 1, 2011, Pages 12-18

  Kumar, Shaji K ^a,c   Gertz, Morie A ^a   Lacy, Martha Q ^a   Dingli, David ^a   Hayman, Suzanne R ^a   Buadi, Francis K ^a   Short Detweiler, Kristen ^a   Zeldenrust, Steven R ^a   Leung, Nelson ^b   Greipp, Philip R ^a   Lust, John A ^a   Russell, Stephen J ^a   Kyle, Robert A ^a   Rajkumar, S Vincent ^a   Dispenzieri, Angela ^a  

^a MAYO CLINIC   (United States)

^b Division of Nephrology and Hypertension   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; TROPONIN T; URIC ACID;

AMYLOIDOSIS; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE;

EID: 78650987230     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/mcp.2010.0480     Document Type: Article

References (38)

1. Kyle RA, Bayrd ED. "Primary" systemic amyloidosis and myeloma: Discussion of relationship and review of 81 cases. Arch Intern Med. 1961;107(3)344-353.
2. Kyle RA, Gertz MA. Primary systemic amyloidosis: Clinical and laboratory features in 474 cases. Semin Hematol. 1995;32(1):45-59.
3. Gertz MA. Diagnosing primary amyloidosis. Mayo Clin Proc. 2002;77(12):1278-1279.
4. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol. 2005;79(4):319-328.
5. Skinner M. AL amyloidosis: The last 30 years. Amyloid. 2000;7(1):13-14.
6. Sanchorawala V, Skinner M, Quillen K, Finn KT, Doros G, Seldin DC. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood. 2007;110(10):3561-3563.
7. Gertz MA, Lacy MQ, Dispenzieri A. Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: A status report. Bone Marrow Transplant. 2000;25(5):465-470.
8. Dispenzieri A, Kyle RA, Lacy MQ, et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: A case-control study. Blood. 2004;103(10):3960-3963.
9. Jaccard A, Moreau P, Leblond V, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med. 2007;357(11):1083-1093.
10. Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: An 8-year study. Ann Intern Med. 2004;140(2):85-93.
11. Dispenzieri A, Lacy MQ, Kyle RA, et al. Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol. 2001;19(14):3350-3356.
12. Kumar SK, Mikhael JR, Buadi FK, et al. Management of newly diagnosed symptomatic multiple myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc. 2009;84(12):1095-1110.
13. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516- 2520.
14. Dispenzieri A, Lacy MQ, Rajkumar SV, et al. Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. Amyloid. 2003;10(4):257-261.
15. Seldin DC, Choufani EB, Dember LM, et al. Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis. Clin Lymphoma. 2003;3(4):241-246.
16. Palladini G, Perfetti V, Obici L, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood. 2004;103(8):2936-2938.
17. Dispenzieri A, Lacy MQ, Zeldenrust SR, et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood. 2007;109(2):465-470.
18. Wechalekar AD, Goodman HJ, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood. 2007;109(2):457-464.
19. Kumar S, Hayman SR, Buadi F, et al. A phase II trial of lenalidomide, cyclophosphamide and dexamethasone (RCD) in patients with light chain amyloidosis [abstract 3853]. Blood (ASH Annual Meeting Abstracts). 2009;114(22):3853.
20. Kastritis E, Roussou M, Migkou M, et al. A phase I/II study of lenalidomide (R) with low dose dexamethasone (d) and cyclophosphamide (C) for patients with primary systemic (AL) amyloidosis [abstract 428]. Blood (ASH Annual Meeting Abstracts). 2009;114(22):428.
21. Wechalekar AD, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica. 2008;93(2):295-298.
22. Zonder JA, Sanchorawala V, Snyder RM, et al. Melphalan and dexamethasone plus bortezomib induces hematologic and organ responses in ALamyloidosis with tolerable neurotoxicity [abstract 746]. Blood (ASH Annual Meeting Abstracts). 2009;114(22):746.
23. Kastritis E, Wechalekar AD, Dimopoulos MA, et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol. 2010;28(6):1031-1037.
24. Sanchorawala V, Wright DG, Rosenzweig M, et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: Results of a phase 2 trial. Blood. 2007;109(2):492-496.
25. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282)457-481.
26. Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22(18):3751-3757.
27. Gertz MA, Zeldenrust SR. Treatment of immunoglobulin light chain amyloidosis. Curr Hematol Malig Rep. 2009;4(2):91-98.
28. Kyle RA, Greipp PR. Primary systemic amyloidosis: Comparison of melphalan and prednisone versus placebo. Blood. 1978;52(4):818-827.
29. Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: Colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997;336(17):1202-1207.
30. Kumar S, Dispenzieri A, Gertz MA. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis [letter]. N Engl J Med. 2008;358(1):91.
31. Kastritis E, Anagnostopoulos A, Roussou M, et al. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica. 2007;92(10):1351-1358.
32. Gertz M, Lacy M, Dispenzieri A, et al. Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis. Leuk Lymphoma. 2008;49(1):36-41.
33. Dispenzieri A, Gertz MA, Kyle RA, et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood. 2004;104(6):1881-1887.
34. Kumar S, Dispenzieri A, Lacy MQ, et al. Serum uric acid: Novel prognostic factor in primary systemic amyloidosis. Mayo Clin Proc. 2008;83(3):297-303.
35. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality: The NHANES I epidemiologic follow-up study, 1971-1992. JAMA. 2000;283(18):2404-2410.
36. Sakai H, Tsutamoto T, Tsutsui T, Tanaka T, Ishikawa C, Horie M. Serum level of uric acid, partly secreted from the failing heart, is a prognostic marker in patients with congestive heart failure. Circ J. 2006;70(8):1006-1011.
37. Hoeper MM, Hohlfeld JM, Fabel H. Hyperuricaemia in patients with right or left heart failure. Eur Respir J. 1999;13(3):682-685.
38. Leyva F, Anker S, Swan JW, et al. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J. 1997;18(5):858-865.